Jul 2, 2026 08:30AM
Jul 2, 2026 08:30AM
Jun 16, 2026 08:02AM
Jun 16, 2026 08:00AM
Jun 4, 2026 04:48PM
Jun 2, 2026 08:01AM
Jun 2, 2026 08:00AM Cingulate Receives Complete Response Letter from FDA for CTx-1301
May 26, 2026 06:59AM
May 14, 2026 08:03AM
May 14, 2026 08:00AM
Apr 6, 2026 04:34PM
Mar 18, 2026 08:00AM
Feb 17, 2026 08:02AM
Feb 17, 2026 08:00AM Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Nov 18, 2025 04:27PM
Nov 13, 2025 08:00AM
Nov 10, 2025 08:01AM
Nov 10, 2025 08:00AM
Oct 28, 2025 08:01AM
Oct 28, 2025 08:00AM
Oct 23, 2025 04:45PM Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
Oct 14, 2025 08:04AM
Oct 14, 2025 08:00AM
Sep 17, 2025 08:45AM
Sep 17, 2025 08:45AM
Aug 21, 2025 04:35PM
Aug 19, 2025 08:45AM
Aug 15, 2025 09:02AM Cingulate places CEO on administrative leave, names interim leadership
Aug 15, 2025 09:00AM
Aug 6, 2025 08:45AM
Aug 6, 2025 08:45AM
Jul 29, 2025 08:01AM
Jul 29, 2025 08:00AM
Jul 9, 2025 08:03AM
Jul 9, 2025 08:00AM Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application
Jun 18, 2025 08:00AM
May 20, 2025 08:03AM
May 20, 2025 08:00AM
May 14, 2025 08:04AM
May 14, 2025 08:00AM
May 8, 2025 04:30PM
Apr 29, 2025 08:00AM Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD
Apr 3, 2025 08:06AM
Apr 3, 2025 08:00AM
Mar 26, 2025 05:00PM
Mar 4, 2025 09:02AM
Mar 4, 2025 09:00AM
Jan 30, 2025 06:40AM
Jan 7, 2025 07:30AM Final Study Completed for Cingulate’s Lead Asset CTx-1301
Dec 23, 2024 07:30AM

325,445 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All